SPR Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$250k | Seed | ||
$1.2m | Seed | ||
$2.2m | Series A | ||
$5.0m | Series A | ||
N/A | $3.9m | Debt | |
N/A | $5.0m | Series B | |
N/A | $1.6m | Grant | |
N/A | $1.9m | Debt | |
$25.0m | Series C | ||
$10.0m | Grant | ||
N/A | $8.0m | Series C | |
$37.0m | Series D | ||
* | $25.0m Valuation: $185m | Series D | |
* | $60.0m | Debt | |
Total Funding | $120m |
Recent News about SPR Therapeutics
EditSPR Therapeutics operates in the medical technology sector, specializing in neuromodulation treatments aimed at providing sustained relief from chronic pain. The company serves healthcare professionals and patients who suffer from various types of chronic and acute pain, including low back pain, shoulder pain, post-amputation pain, and post-operative pain. SPR Therapeutics' flagship product, the SPRINT PNS System, is a minimally invasive, drug-free solution designed for short-term use of up to 60 days, offering long-term pain relief without the need for permanent implants. The system has been clinically proven, with 75% of patients reporting significant sustained pain relief. The company generates revenue by selling its SPRINT PNS System to healthcare providers who then administer the treatment to patients. SPR Therapeutics operates primarily in the United States and targets a market that includes hospitals, pain clinics, and other healthcare facilities. The business model focuses on providing a cost-effective, efficient, and clinically validated alternative to traditional pain management methods, such as surgery and long-term medication use.
Keywords: neuromodulation, chronic pain, acute pain, minimally invasive, drug-free, SPRINT PNS System, healthcare professionals, clinical validation, pain relief, medical technology.